Pain-relaying receptors represent valuable targets for the pharmaceutical industry but classical drug therapies often lead to tolerance, dependence and depression. We recently identified a new pain-related receptor and, in parallel developed, a modulator of this receptor with unique properties. These two findings promise a valuable alternative for the treatment of chronic pain and depressive disorders with possibly reduced side effects.
|Effective start/end date||1/03/19 → 14/11/19|
- FNR - Fonds National de la Recherche: €30,000.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.